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Toxicity and recovery in the pregnant mouse
after gestational exposure to the
cyanobacterial toxin, cylindrospermopsin
N. Chernoﬀ,*a E. H. Rogers,a R. D. Zehr,a M. I. Gage,a D. E. Malarkey,b
C. A. Bradﬁeld,c Y. Liu,c J. E. Schmid,a R. H. Jaskot,a J. H. Richards,a
C. R. Wooda and M. B. Rosena
ABSTRACT: Cylindrospermopsin (CYN) is a tricyclic alkaloid toxin produced by fresh water cyanobacterial species worldwide.
CYN has been responsible for both livestock and human poisoning after oral exposure. This study investigated the toxicity
of CYN to pregnant mice exposed during diﬀerent segments of gestation. The course of recovery and individual responses to
the toxin were evaluated. Adverse eﬀects of CYN were monitored up to 7 weeks post-dosing by clinical examination,
histopathology, biochemistry and gene expression. Exposure on gestational days (GD) 8–12 induced signiﬁcantly more
lethality than GD13–17 exposure. Periorbital, gastrointestinal and distal tail hemorrhages were seen in both groups. Serum
markers indicative of hepatic injury (alanine amino transferase, aspartate amino transferase and sorbitol dehydrogenase) were
increased in both groups; markers of renal dysfunction (blood urea nitrogen and creatinine) were elevated in the GD8–12
animals. Histopathology was observed in the liver (centrilobular necrosis) and kidney (interstitial inﬂammation) in groups
exhibiting abnormal serum markers. The expression proﬁles of genes involved in ribosomal biogenesis, xenobiotic and lipid
metabolism, inﬂammatory response and oxidative stress were altered 24 h after the ﬁnal dose. One week after dosing, gross,
histological and serum parameters had returned to normal, although increased liver/body weight ratio and one instance of
gastrointestinal bleeding was found in the GD13–17 group. Gene expression changes persisted up to 2 weeks post-dosing and
returned to normal by 4 weeks. Responses of individual animals to CYN exposure indicated highly signiﬁcant inter-animal
variability within the treated groups. Copyright © 2010 John Wiley & Sons, Ltd.
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Cylindrospermopsin (CYN) is a potent tricyclic alkaloid toxin produced by fresh water cyanobacteria that has been associated with
toxicity and illness in people after environmental exposures. CYN
and several structurally related chemicals are known to be produced by a number of cyanobacterial species that have been
identiﬁed worldwide. These organisms include Cylindrospermopsis raciborskii in Australia (Ohtani et al., 1992), New Zealand
(Stirling and Quilliam, 2001), Thailand (Li et al., 2001a) and the
USA (Burns, 2008); Umezakia natans in Japan (Harada et al., 1994);
Aphanizomenon ovalisporum in Israel (Banker et al., 1997);
Raphidiopsis curvata in China (Li et al., 2001b); Anabaena bergii in
Australia (Fergusson and Saint, 2003); and Aphanizomenon ﬂosaquae in Germany (Preussel et al., 2006). The widespread occurrence and increasing range of C. raciborskii (Briand et al., 2004),
coupled with its ability to bioaccumulate (White et al., 2006,
2007), indicate that it possesses the potential to cause adverse
health eﬀects in cattle (Thomas et al., 1998) and human
populations.
The health hazard of CYN to human populations was ﬁrst noted
in 1979 following an illness on Palm Island, Australia, that aﬀected
148 people, a majority of whom required hospitalization. The
aﬀected individuals exhibited anorexia, hepatomegaly, abnormal
levels of protein, glucose and ketones and, in later stages, blood

in the urine, acidotic shock, bloody diarrhea and bleeding
mucous membranes (Byth, 1980). Five days prior to the onset of
the symptoms, the reservoir serving as the town’s drinking water
source experienced an algal bloom that was treated with the
algicide, copper sulfate. The water that was distributed to the
town of Palm Island was subsequently chlorinated as part of
the standard water treatment protocol. It was noted that people
living in homes not supplied with water from the reservoir did not
exhibit the symptoms and the possibility of algal toxicity was
suggested (Bourke et al. 1983). Hawkins et al. (1985) identiﬁed C.
raciborskii as one of the most prevalent species of bloom-forming
cyanobacteria in the reservoir at that time and found that administration of this lyophilized algae to mice by intraperitoneal (i.p.)

*Correspondence to: N. Chernoﬀ, US EPA, MD-67, Research Triangle Park,
NC 27711, USA.
E-mail: chernoﬀ.neil@epa.gov
a

US EPA, ORD, National Health and Environmental Eﬀects Research Laboratory,
Research Triangle Park, NC 27711, USA

b
National Institute of Environmental Health Sciences, Cellular and Molecular
Pathology Branch, Research Triangle Park, NC 27709, USA
c
McArdle Laboratory for Cancer Research, University of Wisconsin, 1400 University
Avenue, Madison, WI 53711, USA

Copyright © 2010 John Wiley & Sons, Ltd.
This article is a U.S. government work, and is not subject to copyright in the United States.

J. Appl. Toxicol. 2011; 31: 242–254

Gestational exposure to cylindrospermopsin

J. App. Toxicol. 2011; 31: 242–254

here summarize an eﬀort to characterize the adult post-exposure
toxicity and subsequent course of recovery after CYN exposure
in the post-partum adult females from the 2007 study using
a variety of endpoints: gross observations, clinical chemistry
markers of hepatic and renal function, histopathology and analysis of gene expression in liver tissue.

MATERIALS AND METHODS
Animals
The CD-1 (Swiss–Webster) mice used in the current study were
post-parturitional adult females whose litters were used to evaluate the postnatal developmental toxicity of CYN (Study 1 in
Rogers et al., 2007). The dams were obtained from Charles River
Laboratories (Raleigh, NC, USA) and were singly housed in polycarbonate cages on heat-treated pine shaving bedding in animal
rooms with a controlled temperature range (22–26 °C). They were
fed commercial rodent chow (Purina Prolab®) and water ad
libitum. Maternal animals treated during two diﬀerent dosing
periods were evaluated: early in gestation (GD8–12) or the end of
gestation (GD13–17). GD0 was deﬁned by the presence of a
vaginal sperm plug. All studies were conducted after approval by
the National Health and Ecological Eﬀects Research Laboratory
Institutional Animal Care and Use Committee using the guidelines of the National Research Council (1996).

Compound
CYN used in these studies was supplied by the Australian Water
Quality Center (AWQC), a business unit of the South Australian
Water Corporation, Adelaide, Australia. It was puriﬁed from bulk
cultures of Cylindrospermopsis raciborskii Seenayya Subba Raju
using a proprietary method based on that published by Norris
et al. (2001b). The puriﬁed toxin (C15H21N5O7S; CAS no. 14354590-8, molecular weight 415.42) was characterized using nuclear
magnetic resonance spectrometry, direct infusion electrospray
mass spectrometry and analysis by liquid chromatography using
photodiode array and full-scan positive-ion mode mass spectrometric detection. The toxin was shown to be free from organic
impurities and present as the sodium salt. The estimated purity
was >98%.

Experimental Design
Pregnant mice were administered daily i.p. injections of
50 mg kg-1 CYN in 0.1 ml distilled water for ﬁve days on GD8–12
(42 animals) or GD13–17 (42 animals). The dose was calculated
based on the GD7 weight and the quantity of CYN administered
was not altered during the course of dosing. Concurrent controls
received 0.1 ml distilled water alone on either GD8–12 (26
animals) or GD13–17 (26 animals). Toxicity induced by CYN after
i.p injection indicates that the hepatic and renal eﬀects are qualitatively similar to those obtained after oral dosing, although the
oral route is less toxic by a ~25-fold factor (Falconer et al., 1999).
The similarity of the observed toxicity to the eﬀects noted in the
human population, coupled with the diﬃculty in obtaining an
adequate supply of CYN, was the basis of our choice of the i.p.
route for these studies. Dose–response data from the study (data
not shown, see Rogers et al., 2007) indicated that 50 mg kg-1 per
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injection produced hepatic toxicity as well as toxic eﬀects in
other organs. Ohtani et al. (1992) identiﬁed the hepatotoxic
chemical produced by C. raciborskii as CYN and the toxin has now
been isolated from diﬀerent populations of this species. Saker
et al. (1999) identiﬁed CYN as the probable cause for cattle mortality on a farm in Queensland, and the numerous observations of
bioaccumulation, death and developmental toxicity in a variety
of organisms have led some workers to suggest that the toxin
may be an ecological hazard (see Kinnear et al., 2009).
Mice treated with puriﬁed CYN or with CYN-containing cyanobacterial lyophilates exhibit dose-related hepatic and renal
damage, as well as adverse eﬀects in other organ systems. The
distribution and elimination of CYN has been determined at
doses within the lethal range (Norris et al., 2001a) and the half-life
was found to be in the range of 12 h. At 12 h post-dosing, less
than 5% of the dose remained in the liver with much less present
in the kidneys or blood. Liver damage, characterized by centrilobular necrosis, is a constant ﬁnding in all studies involving the
eﬀects of CYN on mammals (Seawright et al., 1999; Bernard et al.,
2003; Griﬃths and Saker, 2003; Humpage and Falconer, 2003).
Kidney damage involving proximal tubule necrosis is often
noted, as well as other changes in the basic architecture of the
organ (Falconer et al., 1999). Hemorrhages in the lungs (Hawkins
et al., 1985; Bernard et al., 2003) and heart (Hawkins et al., 1985;
Seawright et al., 1999) have been reported. Comparison of exposure to cellular extracts of C. raciborskii and pure CYN revealed
diﬀerences in the type and severity of toxicity, leading a number
of workers to suggest the possibility of other toxins being produced by the cyanobacteria (Falconer et al., 1999; Metcalf et al.,
2002; Humpage and Falconer, 2003). It has been hypothesized
that CYN may be metabolized to an active compound based on
data showing that cytochrome P450 inhibition protects hepatic
cell cultures from CYN eﬀects (Runnegar et al., 1995; Humpage
et al., 2005); and treatment with the cytochrome P450 inhibitor
piperonyl butoxide protected mice from CYN toxicity (Norris
et al., 2002), although the active metabolite(s) have not been
identiﬁed. It should be noted that CYN itself did induce signiﬁcant gene expression changes in three types of cell cultures not
thought to be capable of the metabolic activation of CYN (Bain
et al., 2007). Diﬀerent strains of C. raciborskii can produce diﬀerent toxins, or produce none, and chemical variants of CYN are
present in diﬀerent strains (see Bernard et al., 2003). Two investigators have reported on hepatotoxic eﬀects of cell-free extracts
from C. raciborskii strains that did not contain measurable levels
of CYN (Fastner et al., 2003; Saker et al., 2003).
Our laboratory has been engaged in a series of studies
designed to evaluate the potential developmental toxicity of
cyanobacterial toxins in mammals (microcystin-LR, Chernoﬀ
et al., 2002; anatoxin-a, Rogers et al., 2005; and CYN, Rogers et al.,
2007). In Rogers et al. (2007), the data indicated that maternal
exposure to CYN during pregnancy reduced litter size but was
not otherwise developmentally toxic when administered on gestational days (GD) 8–12, the major period of organogenesis.
When fetuses were exposed later in pregnancy (GD13–17),
however, CYN produced a variety of other adverse eﬀects in addition to reduced litter size. At birth, pups were noted with reduced
weight and bleeding in the gastrointestinal tract and tail similar
to that noted in the pregnant females. All CYN-exposed pups
were cross-fostered to control dams but signiﬁcantly decreased
survival was observed. After weaning, a persistent reduced body
weight was seen up to 1½ years after birth. The oﬀspring toxicity
data are summarized in Rogers et al. (2007). The data reported

N. Chernoﬀ et al.
day induced eﬀects that were similar to those seen in humans (i.e.
hepatic and renal toxicity and gastrointestinal bleeding). Levels
of 32 mg did not induce these eﬀects and doses higher than
50 mg kg-1 per day induced death in the great majority of test
animals. Animals were weighed prior to treatment, during the
dosing period and on the day they were euthanized. Subsets of
animals (two or three controls and three to ﬁve CYN-exposed)
were euthanized the day following the last dose and on posttreatment days 7 and 14 for both exposures; days 28 and 42 for
the GD8–12 exposure, and on days 35 and 49 for the GD13–17
exposures. Blood, liver and kidney samples were obtained at each
time point for further analyses. Endpoints measured included
maternal weight, clinical signs of toxicity, during and after the
dosing period; serum chemistries indicative of hepatic and/or
renal function and general homeostasis, histopathology of liver
and kidney tissues, and hepatic gene expression after the dosing
period.

Blood Collection and Serum Preparation
Animals were euthanized by CO2, and removed when breathing
ceased. Access to the descending aorta was obtained by making
a ‘V’-shaped cut in the abdominal wall and displacing the organs
to visualize the vessel just below the diaphragm. Blood was collected from the descending aorta immediately by inserting a 26G
3/8 inch needle attached to a 1 cm3 syringe into the vessel. The
collected blood was transferred to a 4 ml Vacutainer serum separator tube, allowed to clot for approximately 1 h, and spun at
3000 rpm for 10 min to separate the serum. Serum was transferred to an autoanalyzer cup and stored at -80 °C.

Serum Chemistries
Serum clinical chemistry markers of hepatic and renal function
and injury were measured using the Konelab Arena 30 Clinical
Analyzer (Thermo Clinical Labsystems, Espoo, Finland). Hepatic
function was assessed with AAT (alpha-1 antitrypsin), ALP (alkaline phosphatase), ALT (alanine aminotransferase), AST (aspartate
aminotransferase), LDH (lactate dehydrogenase) and SDH (sorbitol dehydrogenase). Renal function endpoints were BUN (blood
urea nitrogen) and creatinine. Glucose and albumin were measured as markers of general toxicity. All assays were performed
using commercially available clinical chemistry kits. LDH, BUN,
glucose, ALT, AST and ALP kits were obtained from Thermo Electron Corp., Melbourne, Australia. Creatinine and SDH kits are from
Diagnostic Chemicals Ltd, Oxford, CT. Albumin and AAT kits were
obtained from DiaSorin Inc. (Stillwater, MN, USA).

Tissue Preparation for Histological Evaluation
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The liver and kidneys were excised, weighed, and examined for
visible lesions. Liver tissue samples approximately 3 mm thick
were obtained from both the median and left lobes of 56 animals
and ﬁxed in >10¥ volume 10% neutral buﬀered formalin (NBF).
Both kidneys were collected from the same animals, the right
kidney cut longitudinally and the left cross-sectionally, and also
ﬁxed in >10¥ volume 10% NBF. Tissues were placed on a horizontal shaker for at least 18 h and then transferred to 70% ethanol for
not more than 72 h. Sections of liver and kidney from each animal
were evaluated. Tissues were routinely processed, embedded in

wileyonlinelibrary.com/journal/jat

paraﬃn, sectioned at approximately 5 mm, stained with hematoxylin and eosin, and examined histologically. Tissues were
examined using an Olympus BX51, with a 7-ocular nosepiece
ranging from 100¥ to 600¥.

Gene Array and Real-time RT-PCR Analysis of Hepatic Tissue
A tissue sample, adjacent to that collected for histopathology,
was obtained from the liver for gene array analysis. The tissue was
immediately homogenized in TRI reagent (Sigma-Aldrich, St
Louis, MO, USA) and processed through alcohol precipitation on
the same day. RNA pellets were then stored at -80 °C until further
use. Following resuspension in RNase free water, RNA samples
were quantiﬁed using a NanoDrop ND-1000 spectrophotometer
(NanoDrop Products, Wilmington DE), puriﬁed through RNeasy
spin columns (Qiagen, Valencia, CA, USA), evaluated using a 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), and subsequently stored at -80 °C. Only samples with an RNA Integrity
number of at least 8.5 (2100 Expert software, version B.01.03)
were included in the study. RNA labeling, microarray hybridization and scanning, and data reduction were done at the EDGE2
Program, University of Wisconsin, using a two-channel customspotted microarray developed for evaluation of liver toxicity (see
Hayes et al., 2005 for details on generation of arrays and techniques used to obtain the gene array data).
Real-time RT-PCR analysis was performed using genes selected
to verify the eﬀects noted by microarray analysis. These analyses
were conducted using the same RNA samples utilized for
microarray analysis with the addition of either two or three
samples per group from the GD13–17 dose group that were
included to evaluate treatment recovery at 7, 16, and 28 days
post-dosing. Two micrograms total RNA was digested using 2
units DNaseI (no. M6101, Promega Corporation, Madison, WI,
USA) for 30 min at 37 °C followed by 10 min at 65 °C in a buﬀer
containing 40 mM Tris (pH 8.0), 10 mM MgSO4 and 1 mM CaCl2. The
RNA was then quantiﬁed using a Quant-iT RiboGreen RNA assay
kit according to the manufacturer’s protocol (no. R11490, Invitrogen Corporation, Carlsbad, CA, USA) and approximately 1.5 mg
RNA reverse transcribed using a High Capacity cDNA Archive Kit
according to the provided protocol (no. 4322171, Applied Biosystems, Foster City, CA, USA). Ampliﬁcation was performed on an
Applied Biosystems model 7900HT Fast Real-Time PCR System in
duplicate using 25 ng cDNA and TaqMan Universal PCR Master
Mix (no. 4304437, Applied Biosystems) in a total volume of 12 ml.
Beta-2-microglobulin (B2m, Entrez no. 12010) was used as an
endogenous reference gene. The following TaqMan assays
(Applied Biosystems) were included in the study: B2m (no.
Mm00437762_m1), Ehhadh (no. Mm00470091_s1), Cyp2b10
(no. Mm00456591_m1), Cyp2E1 (no. Mm00491127_m1), Fabp1
(Mm00444340), Gclc (Mm00802655_m1), Nfe2l2 (Mm00477784_
m1), Rpl6 (Mm01198491_g1), Rps12 (Mm03030276_g1),
F10 (Mm00484177_m1), C4a (no. Mn00550309_m1), C9
(Mm00442739_m1) and Hpx (Mm00457510_m1). Fold change
was estimated using the 2-DDCT method of Livak and Schmittgen
(2001).

Data Evaluation
The weight and clinical chemistry data were analyzed by analysis
of variance (ANOVA) using SASversion 9.2 software (SAS Institute
Inc., 2008). Means, standard errors and coeﬃcients of variation

Copyright © 2010 John Wiley & Sons, Ltd.
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were calculated in Proc Means. In many cases the variances of
outcome measures were not homogeneous across the treatment
groups; therefore a Box Cox transformation was calculated (SAS
Proc Transreg) to stabilize the variance (Box and Cox, 1964). Proc
GLM was used to perform one-way ANOVAs on the transformed
data across the 10 treatment by day groups. Pairwise t-tests were
calculated within the ANOVAs to test for diﬀerences between the
treated and control groups at each time point; a Bonferroni correction was used to adjust for multiple comparisons. Where a
direction of change was predicted a priori, a one-sided t-test was
used; otherwise a two-sided test was used. Levene’s test (Levene,
1960) was used to evaluate the statistical signiﬁcance of the difference in variance between the treated group one day after the
last dose and the pool of all other treatment groups. In the array
data, gene transcripts that deviated more than 2-fold from
control were further evaluated for relevance to canonical pathways and biological functions using Ingenuity Pathways Analysis
(Ingenuity Systems, www.ingenuity.com). Heat maps were generated using Eisen Lab Cluster and Treeview software (http://
rana.lbl.gov/EisenSoftware.htm).

in three of four euthanized one day after the last dose and 1 of 5
on the seventh day after the last dose. A single instance of bleeding around the eyes was observed. Treated animals gave birth
earlier than controls with 58% of the CYN animals giving birth by
1:00 p.m. on GD18/PND0 as compared with 31% of the controls.
No other clinical signs of toxicity were observed in either group
after 7 days post-dosing.

Serum Biochemistries and Organ/body Weight Ratios
The data for the GD8–12 and GD13–17 dose groups are summarized in Tables 2 and 3. The mean levels of three markers of
hepatic function (AAT, ALT and AST) were signiﬁcantly elevated
(P ⱕ 0.01) on the day following the last dose in both the GD8–12

RESULTS
Clinical Findings
Clinical signs of toxicity are summarized in Table 1. GD8–12
animals were aﬀected earlier and to a greater degree than the
GD13–17 group. Maternal weight gain was signiﬁcantly reduced
after the initial dose of CYN in the GD8–12 animals and this eﬀect
continued throughout the treatment period (Fig. 1a). After the
ﬁfth dose, maternal weights were signiﬁcantly reduced, but this
eﬀect did not persist (Table 2). Vaginal bleeding was observed on
GD11 following the third dose of CYN along with reduced activity, blood in the distal area of the tail, and mild to moderate
hemorrhage in and around one or both eyes following the fourth
dose. Vaginal and/or periorbital hemorrhages were often associated with death before GD17. Mortality and moribidity-required
euthanasia initially occurred after the fourth dose on GD12 (8/42
animals). Eight died on GD13 after the ﬁfth dose with an additional ﬁve moribund animals euthanized at that time. Single
instances of death occurred on GD16 and GD18. Gestational
length in treated animals did not diﬀer from controls.
The body weights of the GD13–17 dosed animals were not as
severely aﬀected; the only signiﬁcant weight diﬀerences noted
were after the second dose (Fig. 1b) and 49 days after the last
dose (Table 3). There were no deaths in this group. Intraluminal
blood in the gastrointestinal tract of GD13–17 animals was found

Table 1.

Figure 1. Maternal weight change during cylindrospermopsin administration: (A) GD8–12; (B) GD13–17. Note that animals in the GD13–17
group had given birth after the ﬁfth dose and therefore these data are not
shown.

Maternal eﬀects after exposure to 50 mg/kg cylindrospermopsin

Exposure

Treatment

No. mice

No. died (%)

Vaginal

GD 8–12

Control
CYN
Control
CYN

26
42
26
42

0
23(55)b
0
0

0
13
0
0

GD 13–17

Bleeding (no.)a
Orbital
Tail
0
2
0
1

0
2
0
0

Gastrointestinal
0
0
0
3c

a

Multiple eﬀects occurred in single animals.
p < 0.01.
c
Two instances of intestinal bleeding were noted in the four animals killed on GD 13 and one instance was seen 7 days post-dosing.
b
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3

3

3

3

3

3

5

3

L/BW

6.2 ⫾ 0.2
6.6
6.5 ⫾ 0.5
15.8
6.0 ⫾ 0.6
17.1
6.3 ⫾ 0.6
21.1
5.6 ⫾ 0.1
3.5
6.1 ⫾ 0.5
13.8
5.2 ⫾ 0.4
13.8
5.4 ⫾ 0.4
11.4
4.7 ⫾ 0.1
2.1
5.0 ⫾ 0.1
4.9

Kill Wt

40.2 ⫾ 1.5
6.5
32.2* ⫾ 2.1
14.4
36.0 ⫾ 2.4
11.6
34.9 ⫾ 1.7
10.7
34.4 ⫾ 1.7
8.7
34.6 ⫾ 0.2
1.2
36.8 ⫾ 2.0
9.4
37.6 ⫾ 0.6
2.1
38.2 ⫾ 2.3
10.5
36.0 ⫾ 0.8
3.9

1.1 ⫾ 0.1
9.6
1.2 ⫾ 0.1
22.0
1.3 ⫾ 0.1
3.3
1.2 ⫾ 0.1
8.9
1.2 ⫾ 0.1
5.2
1.3 ⫾ 0.1
7.8
1.0 ⫾ 0.1
1.3
1.2 ⫾ 0.1
4.7
1.2 ⫾ 0.1
13.3
1.1 ⫾ 0.1
15.1

K/BW
10.3 ⫾ 0.6
9.8
34.1* ⫾ 16.9
70.1
9.8 ⫾ 0.1
1.9
10.0 ⫾ 0.5
10.7
9.9 ⫾ 0.2
3.3
9.1 ⫾ 1.1
21.3
10.5 ⫾ 0.9
14.9
9.8 ⫾ 0.6
10.1
10.4 ⫾ 0.3
4.6
10.2 ⫾ 0.2
3.8

AAT
(mg dl-1)
50.3 ⫾ 2.0
6.8
59.1 ⫾ 4.1
14.0
52.0 ⫾ 8.8
28.9
64.3 ⫾ 10.4
36.0
93.9 ⫾ 6.5
11.9
80.0 ⫾ 7.3
15.8
85.2 ⫾ 6.6
13.5
57.0 ⫾ 5.1
15.5
55.2 ⫾ 3.9
12.3
72.6 ⫾ 7.7
18.3

ALP
(IU l-1)
30.6 ⫾ 2.3
12.8
112.1* ⫾ 37.0*
65.4
37.8 ⫾ 6.0
27.3
38.2 ⫾ 0.4
22.3
47.3 ⫾ 6.3
23.0
48.3 ⫾ 3.0
6.6
46.3 ⫾ 5.4
20.3
38.8 ⫾ 9.2
41.2
45.1 ⫾ 7.4
28.4
42.9 ⫾ 5.7
23.1

ALT
(IU l-1)
82.1 ⫾ 4.8
10.2
219.3* ⫾ 35.9*
40.6
65.7 ⫾ 1.8
4.8
65.2 ⫾ 3.2
11.1
73.7 ⫾ 8.8
20.7
125.5 ⫾ 13.1
18.0
65.9 ⫾ 4.6
12.0
32.2 ⫾ 18.6
68.4
81.3 ⫾ 7.4
15.8
65.6 ⫾ 6.4
16.9

AST
(IU l-1)
378.5 ⫾ 22.4
10.3
692.2 ⫾ 361.8*
98.7
255.2 ⫾ 43.7
29.6
227.1 ⫾ 16.8
16.5
309.9 ⫾ 27.6
15.4
451.9 ⫾ 51.3
19.7
290.0 ⫾ 91.9
54.9
247.6 ⫾ 65.4
45.7
296.2 ⫾ 5.5
3.2
207.1 ⫾ 6.3
5.3

LDH
(IU l-1)
39.9 ⫾ 3.4
14.6
50.5 ⫾ 7.7*
40.9
32.1 ⫾ 3.8
20.7
33.7 ⫾ 3.5
23.3
41.8 ⫾ 1.7
7.2
57.1 ⫾ 7.2
21.9
35.7 ⫾ 8.9
43.1
35.2 ⫾ 8.0
39.4
36.8 ⫾ 0.6
2.7
30.8 ⫾ 3.8
21.5

SDH
(IU l-1)
12.1 ⫾ 1.2
16.7
129.3* ⫾ 30.9*
50.6
17.8 ⫾ 0.7
6.5
15.4 ⫾ 2.5
36.6
17.8 ⫾ 1.4
13.3
20.9 ⫾ 2.0
16.7
20.6 ⫾ 5.3
44.2
16.6 ⫾ 4.4
45.9
22.1 ⫾ 0.1
0.4
19.6 ⫾ 0.6
4.9

BUN
(mg dl-1)
0.35 ⫾ 0.01
6.61
0.60** ⫾ 0.13*
64.60
0.45 ⫾ 0.04
14.64
0.39 ⫾ 0.02
8.87
0.54 ⫾ 0.05
17.13
0.43 ⫾ 0.05
19.55
0.39 ⫾ 0.02
7.71
0.37 ⫾ 0.01
6.80
0.40 ⫾ 0.00
1.82
0.40 ⫾ 0.00
11.38

Creatinine
(mg dl-1)
150.9 ⫾ 15.4
17.7
130.2 ⫾ 11.4
21.5
218.2 ⫾ 31.7
25.1
204.1 ⫾ 22.8
25.0
259.5 ⫾ 11.3
7.5
207.9 ⫾ 13.3
11.1
281.3 ⫾ 1.8
1.1
244.9 ⫾ 13.5
9.6
278.3 ⫾ 24.6
15.3
247.7 ⫾ 3.3
2.3

Glucose
(mg dl-1)

2.2 ⫾ 0.0
0.6
0.9* ⫾ 0.2
46.1
3.4 ⫾ 0.3
14.3
3.1 ⫾ 0.1
7.7
3.4 ⫾ 0.1
7.5
3.4 ⫾ 0.1
5.6
3.0 ⫾ 0.1
7.0
3.1 ⫾ 0.2
10.6
3.1 ⫾ 0.1
4.7
3.1 ⫾ 0.1
4.7

Albumin
(g dl-1)
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Con
%cv
Cyn
%cv
Con
%cv
Cyn
%cv
Con
%cv
Cyn
%cv
Con
%cv
Cyn
%cv
Con
%cv
Cyn
%cv

5

3

4

2

5

3

5

3

4

No.
2

Kill Wt
30.1 ⫾ 3.0
14.1
31.5 ⫾ 2.7
17.2
30.3 ⫾ 1.3
7.6
32.1 ⫾ 1.5
10.4
33.1 ⫾ 1.0
5.5
31.9 ⫾ 0.6
4.0
34.2 ⫾ 1.3
5.4
33.1 ⫾ 1.6
9.9
38.2 ⫾ 1.0
4.3
33.1 ⫾ 0.9**
5.9

L/BW
6.6 ⫾ 0.6
13.5
7.5 ⫾ 0.9
24.6
5.6 ⫾ 0.3
9.3
8.5 ⫾ 0.6*
17.0
4.9 ⫾ 0.2
8.5
5.7 ⫾ 0.3
12.5
4.5 ⫾ 0.3
9.5
5.0 ⫾ 0.2
9.2
3.9 ⫾ 0.1
1.7
4.6 ⫾ 0.2
12.0

K/BW
1.3 ⫾ 0.1
15.9
1.2 ⫾ 0.2
26.3
1.3 ⫾ 0.1
15.8
1.4 ⫾ 0.1
6.4
1.4 ⫾ 0.1
5.1
1.3 ⫾ 0.1
8.0
1.2 ⫾ 0.1
9.7
1.2 ⫾ 0.1
3.7
1.0 ⫾ 0.1
5.4
1.3 ⫾ 0.1
66.0

AAT
(mg dl-1)
9.2 ⫾ 0.1
2.1
28.5* ⫾ 5.5*
38.3
10.7 ⫾ 0.1
0.5
12.2 ⫾ 1.3
24.6
9.7
nd
9.6 ⫾ 0.2
5.0
9.9 ⫾ 0.2
3.4
10.0 ⫾ 0.3
5.6
8.9 ⫾ 0.7
14.5
10.0 ⫾ 0.2
5.4

ALP
(IU l-1)
56.5 ⫾ 2.7
6.8
77.7 ⫾ 13.4
34.5
86.6 ⫾ 5.4
10.8
82.9 ⫾ 6.1
16.4
92.7 ⫾ 10.8
20.2
76.6 ⫾ 8.4
24.6
82.8 ⫾ 7.2
12.3
73.7 ⫾ 8.8
24.0
73.5 ⫾ 6.2
14.6
65.6 ⫾ 1.5
5.2

ALT
(IU l-1)
42.3 ⫾ 4.9
16.2
325.2* ⫾ 191.2*
117.6
46.8 ⫾ 2.0
7.4
74.7 ⫾ 31.6
94.8
41.6 ⫾ 2.1
8.8
40.6 ⫾ 2.2
11.9
49.4 ⫾ 9.2
26.3
46.0 ⫾ 6.0
26.3
42.0 ⫾ 5.2
21.6
35.3 ⫾ 2.5
16.1

Clinical chemistries and organ/body weight ratios for GD13–17 animals
AST
(IU l-1)
57.4 ⫾ 3.9
9.7
314.1* ⫾ 90.6*
57.7
80.1 ⫾ 17.0
36.8
70.2 ⫾ 8.3
26.6
60.4 ⫾ 1.1
3.0
64.1 ⫾ 5.0
17.6
73.1 ⫾ 9.5
18.3
63.7 ⫾ 2.2
7.0
61.7 ⫾ 2.9
8.2
57.2 ⫾ 3.9
15.3

LDH
(IU l-1)
277.1 ⫾ 49.3
25.1
992.1* ⫾ 232.9*
46.9
243.6 ⫾ 75.1
53.4
340.9 ⫾ 74.4
48.8
233.7 ⫾ 31.7
23.5
294.2 ⫾ 38.8
29.5
271.8 ⫾ 38.8
20.2
247.5 ⫾ 39.3
31.7
243.0 ⫾ 28.5
20.3
183.7 ⫾ 17.7
21.5

SDH
(IU l-1)
33.3 ⫾ 8.2
35.1
119.0* ⫾ 41.9*
70.3
30.9 ⫾ 8.2
46.0
44.5 ⫾ 8.7
44.1
36.5 ⫾ 8.4
40.0
34.2 ⫾ 4.9
31.9
36.1 ⫾ 3.4
13.4
32.6 ⫾ 2.5
15.1
35.1 ⫾ 3.9
19.4
27.6 ⫾ 1.7
13.7

BUN
(mg dl-1)
26.2 ⫾ 0.1
0.8
33.9 ⫾ 6.2*
36.3
17.4 ⫾ 1.0
10.2
19.1 ⫾ 3.2
37.4
12.7 ⫾ 1.7
23.2
14.8 ⫾ 1.4
21.1
21.1 ⫾ 4.5
29.9
12.7 ⫾ 1.1
17.1
21.6 ⫾ 2.2
17.5
15.4 ⫾ 0.7
10.7

Creatinine
(mg dl-1)
0.45 ⫾ 0.02
5.03
0.46 ⫾ 0.04
17.68
0.42 ⫾ 0.03
9.97
0.41 ⫾ 0.02
11.06
0.45 ⫾ 0.05
17.32
0.45 ⫾ 0.03
15.73
0.42 ⫾ 0.01
4.04
0.41 ⫾ 0.02
7.93
0.40 ⫾ 0.05
23.62
0.42 ⫾ 0.02
8.37

Glucose
(mg dl-1)
210.7 ⫾ 9.7
6.5
97.2* ⫾ 11.9
24.5
240.3 ⫾ 41.4
22.6
214.1 ⫾ 5.0
5.2
324.6 ⫾ 36.5
19.5
277.2 ⫾ 16.5
13.3
327.6 ⫾ 79.9
34.5
312.5 ⫾ 17.6
11.3
235.9 ⫾ 12.6
9.2
263.2 ⫾ 21.6
18.3

Albumin
(g dl-1)
3.6 ⫾ 0.7
26.8
1.7* ⫾ 0.4*
52.3
3.5 ⫾ 0.2
6.4
3.2 ⫾ 0.2
6.6
2.9 ⫾ 0.2
9.5
3.5 ⫾ 0.1
2.9
3.1 ⫾ 0.1
3.9
3.2 ⫾ 0.1
2.9
3.1 ⫾ 0.1
4.6
3.1 ⫾ 0.1
5.5

%cv, % coeﬃcient of variation.
*P < 0.01.
**P < 0.05.
Note that signiﬁcances are given for both means and variance.
AAT, antitrypsin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; SDH, sorbitol dehydrogenase; L/BW, liver/body weight ratio; BUN, blood urea nitrogen; K/BW, kidney/body weight ratio.
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Days after
last dose
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Table 3.

%cv, % coeﬃcient of variation.
*P < 0.01.
**P < 0.05.
Note that signiﬁcances are given for both means and variance.
AAT, antitrypsin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; SDH, sorbitol dehydrogenase; L/BW, liver/body weight ratio; BUN, blood urea nitrogen; K/BW, kidney/body weight ratio.
***AAT, two samples; LDH, BUN, four samples.
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Clinical chemistries and organ/body weight ratios for GD8–12 animals

Days after
last dose

Table 2.
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Gestational exposure to cylindrospermopsin

Figure 2. Toxicity proﬁles of averaged GD8–12 and GD13–17 animals’ responses to CYN and individual animals within each of these dosing
regimen groups. The left y-axis represents data on body and organ weights and general markers of metabolic homeostasis compared with control
values (controls = 100%). The right y-axis shows the degree of change in the hepatic and renal markers of toxicity as a percentage of the control values
(controls = 100%).

J. App. Toxicol. 2011; 31: 242–254

Measures of variance (standard error) and variance relative to
the mean (percentage coeﬃcient of variation or %cv) are listed in
Tables 2 and 3. The variability in response across GD8–12 CYNexposed individuals was signiﬁcantly greater one day after the
last dose for serum levels of ALT, AST, LDH, SDH, BUN, creatinine
and the kidney/body weight ratio (P ⱕ 0.01). The response of the
GD13–17 animals was generally similar with the following exceptions: the variance of AAT was signiﬁcantly increased (P ⱕ 0.01),
as were the serum levels of albumin (P ⱕ 0.01), but no signiﬁcant
eﬀects were noted for either creatinine or kidney/body weight
ratios.
An illustration of individual diﬀerences in response to CYN is
shown in Fig. 2. This ﬁgure summarizes the GD8–12 and GD13–17
group‘toxicity proﬁles’of weight changes and clinical chemistries
as well as individual proﬁles of pairs of animals selected because

Copyright © 2010 John Wiley & Sons, Ltd.
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and GD13–17 groups. LDH and SDH were signiﬁcantly elevated
(P < 0.01) in the GD13–17 group while showing a trend in the same
direction in the GD8–12 group. At this time, serum albumin levels
were signiﬁcantly reduced (P ⱕ 0.01) in both groups. One day after
the last dose, both BUN (P ⱕ 0.01) and creatinine (P ⱕ 0.05) levels
were signiﬁcantly elevated in the GD8–12 group. Serum glucose
levels were signiﬁcantly lower (P ⱕ 0.01) in the GD13–17 group
while the serum glucose levels showed a trend in the same direction in the GD8–12 group. Values for clinical chemistries returned
to normal 7 days after the last dose in both groups. No signiﬁcant
diﬀerences in kidney/body weight ratio were noted in either
group.The liver/body weight ratio was not diﬀerent in the GD8–12
group but were signiﬁcantly elevated in the GD13–17 animals on
day 7 post-dosing (P < 0.01) and remained higher than the control
values for the remainder of the study.

N. Chernoﬀ et al.

Table 4.

Incidence of histologic lesions in female mice treated with CYN either during GD8–12 or GD13–17
GD8–12

Dose in mg/kg
a

Hepatocyte necrosis
Nephrosis and/or renal inflammation

GD13–17

0

50

0

50

1/9 (11%)
0/9

7/19 (37%)
5/19 (26%)

1/9 (11%)
0/9

4/19 (21%)
0/19

a

Predominantly individual cell necrosis in centrilobular and/or subcapsular regions and accompanied by subacute to chronic
inﬂammation.

of the range of responses they displayed. Although the type and
the direction of changes induced by CYN were consistent, the
degree of response varied considerably among animals. For
example, in the GD13–17 animals illustrated, animals 29 and 69
diﬀered from the group average. Animal 29 exhibited ocular
bleeding, liver pathology, reduced body weight, increased liver/
body weight ratio and extremely high levels of hepatic toxicity
markers, eﬀects that were either absent or present to a much
lesser degree in animal 69.

Histopathology
The incidence of histologic lesions is given in Table 4. Minimal to
moderate centrilobular hepatocyte necrosis and apoptosis, primarily of scattered individual cells, were observed in 1/9 (11%) of
both GD8–12 and GD13–17 controls compared with 7/19 (37%)
GD8–12 and 4/19 (21%) of GD13–17 CYN-exposed animals one
day after the last dose. Scattered hepatocytes were either individually dying (via necrosis and/or apoptosis) or occasionally
undergoing coagulative necrosis in groups, sometimes accompanied by varying degrees of inﬂammatory cell inﬁltrates (lymphocytes with occasional macrophages and neutrophils; Fig. 3).
Lesions generally aﬀected <10% of the parenchyma. Minimal to
moderate kidney lesions were noted only in 5/19 (26%) treated
GD8–12 dams. Aﬀected animals had multifocal, minimal to moderate, chronic interstitial nephritis or minimal nephrosis seen as
acute tubular epithelial necrosis (data not shown).

Gene Array and Real-time PCR Analyses
Microarray analysis

Figure 3. Photomicrographs of H&E sections of liver from a mouse
treated with 50 mg kg-1 of cylindrospermopsin during GD13–17 and killed
on GD18, demonstrating centrilobular necrosis and apoptosis. The ﬁgures
show diﬀerent areas of the central vein (CV). Magniﬁcation is (A) 180¥ and
(B) 380¥. The arrows in (A) point to cell death and inﬂammation; arrows in
B point to apoptotic hepatocytes.
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The transcriptional response to CYN was similar among individual animals and did not diﬀer markedly across the two exposure groups. Canonical pathways or functional groups found to
be altered by CYN one day following the last dose included ribosome biogenesis (Fig. 4), lipid metabolism (Fig. 5a), xenobiotic
metabolism (Fig. 5b), the inﬂammatory response (Fig. 6a) and the
nuclear factor E2-related factor 2 (Nrf2) response to oxidative
stress (Fig. 6b).

similar for most genes, although scattered diﬀerences in the
degree of changes were observed in individual animals. Discrepancies were observed with regard to expression of Nrf2, especially among animals dosed on GD8–12. Increased expression of
glutamate cysteine ligase (Gclc), a Nrf2 regulated gene (Wild
et al., 1999; Han et al., 2008), was conﬁrmed in all but one animal.
Hepatic recovery from the changes induced by CYN was apparent
as early as one week after dosing with expression levels close to
control levels by post-dosing day 28.

Real-time qRT-PCR analysis

DISCUSSION

The results for real-time quantitative RT-PCR are shown in Fig. 7.
The genes chosen for PCR analysis represent a subset of genes
shown by microarray analysis to be altered by CYN in the livers of
the adult mice. A comparison of the microarray and RT-PCR data
indicates that the direction of the gene expression changes was

Cylindrospermopsin is a toxin that is produced by a variety of
cyanobacterial species, especially C. raciborskii, which has been
rapidly spreading globally and is now the source of many blooms
worldwide. It has already been shown to have the potential to
induce human toxicity via chlorinated drinking water. Surveys

wileyonlinelibrary.com/journal/jat
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Gestational exposure to cylindrospermopsin

Figure 4. Eﬀect of CYN on genes associated with ribosome. Many of
the genes in this functional group were up-regulated by CYN in both
dose groups. Red and green correspond to up- and down-regulation,
respectively.

J. App. Toxicol. 2011; 31: 242–254
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have identiﬁed blooms of C. raciborskii in Indiana (Jones and
Sauter, 2005), Illinois (Holland et al., 2006) and Florida (Burns,
2008) in the USA. This organism also tends to decrease the biodiversity of phytoplankton species when it becomes established in
a water system (Dobberfuhl, 2005). Increased dependence on
surface waters for drinking coupled with climatic conditions that
promote cyanobacterial growth make C. raciborskii an increasing
threat to both the environment and human populations (Briand
et al., 2004; Jones and Sauter, 2005; Burns, 2008).
Exposure of pregnant mice to CYN on GD8–12 induced greater
toxicity than on GD13–17. Toxicity in GD8–12 animals was ﬁrst
noted as a signiﬁcant reduction in weight gain after the initial

dose that persisted throughout the dosing period. In contrast,
there was no clear pattern of weight change in the GD13–17
dams. Mortality and vaginal bleeding occurred in 55 and 31% of
the GD8–12 animals, respectively, vs 0% in the GD13–17 group.
The reason for these diﬀerences is unknown. If CYN is distributed
across the fetal–maternal compartments, diﬀerences in maternal
toxicity noted between treatment groups could be related to the
changing volume of the embryo/fetal compartment during gestation. Although placental transfer studies of CYN have not been
done, toxicity of CYN to pups exposed late in gestation (GD13–
17) indicates an absence of a placental barrier. The GD13–17
animals have a signiﬁcantly larger fetal compartment and therefore the maternal exposure and associated toxicity would be
much less at this time. In contrast, early in gestation the dose to
the maternal organism exclusive of the embryo/fetus would be
signiﬁcantly higher and the resultant maternal toxicity greater.
The bleeding that occurred in treated animals is a relatively
uncommon xenobiotic-induced eﬀect. Hemorrhage in multiple
sites in both the dam and fetus suggests a CYN-induced coagulopathy and/or vascular injury consistent with an alteration in
coagulation factors and the coagulation cascade. Gene expression analysis indicated a down regulation of Coagulation Factor
X. Deﬁciencies in the expression of this gene have been associated with bleeding in both humans (Peyvandi et al., 1998) and
mice (Dewerchin et al., 2000), but a relationship to CYN-induced
bleeding remains to be determined. Similar responses to CYN
intoxication, i.e. bloody diarrhea and bleeding in the mucous
membranes, were noted in aﬀected humans (Byth, 1980). Protein
synthesis inhibition is generally considered to be a key component of CYN-induced toxicity (Terao et al., 1994; Froscio et al.,
2001, 2008; Metcalf et al., 2002; Neumann et al., 2007; Falconer,
2008). The degree to which such inhibition is responsible for CYN
toxicity remains unknown. Froscio et al. (2003) failed to show a
relation between the degree of protein synthesis inhibition in
mouse hepatocytes and the leakage of LDH into the medium.
They concluded that protein synthesis inhibition may not be fully
responsible for CYN hepatocyte toxicity. Considerable cell proliferation in dermal and mouth epithelial layers of Bufo marinus
tadpoles exhibiting CYN-induced toxicity was not consistent with
general protein synthesis inhibition (Kinnear et al., 2007). The
protein synthesis inhibitor, cycloheximide, does not induce liver
necrosis (Farber, 1971) while others such as carbon tetrachloride
(Smuckler et al., 1961) and galactosamine (Decker and Keppler,
1974) do result in hepatic necrosis. The bleeding that is a prominent characteristic of CYN toxicity has been reported after exposure to the protein synthesis inhibitor, T-2, a fungal metabolite.
Also, placental bleeding has been described in both rats (Doi
et al., 2008) and mice (Schiefer, 1984; Rousseaux et al., 1986)
exposed to T-2. This bleeding did not occur after the exposure to
the protein synthesis inhibitor, emetine, but adverse clinical signs
included vomiting and diarrhea (National Cancer Institute, 1978).
Hepatic toxicity was indicated by serum markers of liver function and histopathology. Elevations in AAT, ALP, ALT, AST, LDH and
SDH indicated that the liver was adversely aﬀected in both
GD8–12 and GD13–17 dams one day after the last dose. Biochemical indicators of hepatic damage returned to normal after
one week in the GD13–17 group and by 4 weeks in the GD8–12
animals. Reduction of serum albumin was also noted in both
groups, indicating possible renal and/or hepatic injury. The
hepatic histopathology consisted of centrilobular hepatocyte
necrosis and was similar in both the GD8–12 and GD13–17
groups. These eﬀects were not observed one week after dosing.

N. Chernoﬀ et al.

Figure 5. Eﬀect of CYN on genes related to lipid metabolism (A) and xenobiotic metabolism (B). Genes in these functional categories showed uniform
changes across animals in each treatment group, an eﬀect consistent with hepatic injury. Red and green correspond to up- and down-regulation,
respectively.
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The liver has been described as a primary site of CYN-induced
toxicity (Hawkins et al., 1985; Harada et al., 1994; Bernard et al.,
2003; Griﬃths and Saker, 2003; Terao et al., 1994). Our data do not
necessarily support this hypothesis. Serum chemistries indicated
similar hepatic toxicity in both treatment groups. However, ﬁve
out of six serum markers indicative of hepatic toxicity showed
greater changes from control values in the GD13–17 group,
although signiﬁcantly less lethality was seen in these animals. The
incidence of hepatic histopathology was also similar in both
groups but the severity of the changes was inconsistent with liver
damage as a cause of death.
Markers for renal injury, BUN and creatinine, were increased in
the GD8–12 but not in GD13–17 animals. Although these data are
consistent with histopathological ﬁndings of renal tissue damage
(nephrosis) in the GD8–12 group, it should be noted that the
observed increase in BUN and disproportional slight increase in
creatinine suggest that other possible sources, such as intraluminal hemorrhage, may have contributed to elevated BUN.
Similar changes in gene expression were observed in both
dose groups when evaluated by microarray analysis 24 h after the
ﬁnal dose of CYN. These changes included altered expression of
genes associated with ribosome biogenesis, lipid metabolism,
xenobiotic metabolism, the inﬂammatory response and the Nrf2
response to oxidative stress. Transcriptional changes involving

wileyonlinelibrary.com/journal/jat

genes related to fatty acid metabolism and ribosome biogenesis
were also reported by Chung et al. (2005) in the rat liver following
a single toxic exposure to carbon tetrachloride, indicating that
these changes may be common to hepatic injury. In addition,
reduced cytochrome P450 enzyme activity and/or decreased
expression of cytochrome P450 genes by speciﬁc inducers of liver
inﬂammation has been described elsewhere (for reviews, see
Gerrish and Malarkey, 2007; Renton, 2004; Morgan, 2001) and has
previously been reported for CYN-exposed mice (Terao et al.,
1994). Indeed, CYN is a known hepatotoxin (Seawright et al.,
1999; Fastner et al., 2003; Terao et al., 1994) and while liver injury
was apparent in the current study, the inability to draw a distinction between the two dose groups based on the gene expression
data provides additional support to the argument that liver injury
may not be the principal mode of action associated with the
toxicity observed in CYN-expose mice. Additional studies using
broad gene expression arrays at diﬀerent time points following
CYN exposure are currently underway and may provide a more
complete understanding of the course of CYN-induced toxicity.
In recent years, there has been increased interest in identifying
factors that are responsible for the range of responses observed
within a population following exposure to a toxicant (see Fraser,
2004; Varki et al. 2008; Liao et al., 2008). Several investigators have
noted the tendency of CYN to induce an unusually wide breadth

Copyright © 2010 John Wiley & Sons, Ltd.
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Gestational exposure to cylindrospermopsin

Figure 6. Eﬀect of CYN on genes associated with the inﬂammatory response (A) and the Nrf2 response to oxidative stress (B). Changes probably
related to liver injury were observed across animals in each dose group. Red and green correspond to up- and down-regulation, respectively.

J. App. Toxicol. 2011; 31: 242–254

Copyright © 2010 John Wiley & Sons, Ltd.

wileyonlinelibrary.com/journal/jat

251

Figure 7. Real-time PCR evaluation of selected genes. Good agreement was found between the results from either microarray or RT-PCR analysis.
Diﬀerences were observed with respect to expression of Nrf2, especially among animals dosed on GD8–12, although increased expression of glutamate
cysteine ligase (Gclc), an Nrf2 regulated gene, was conﬁrmed in all but one animal. Red and green correspond to up- and down-regulation, respectively.
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of individual responses to similar exposures in both mammals
(Seawright et al., 1999; Norris et al., 2001a) and amphibians
(White et al., 2007). The current study appears to support these
observations. The degree of individual variability in response to
speciﬁc toxicants is expressed by the standard error and the percentage coeﬃcient of variation (%cv) of the treatment groups.
The signiﬁcant increase in variance seen in the treated groups
was evidence of the tendency of CYN to elicit a wide range of
individual responses. The %cv supports these observations in
that the increase in variance relative to the mean is also highly
noteworthy. The variance was signiﬁcantly increased in both
GD8–12 and GD13–17 groups for most of the hepatic toxicity
measures. The variability in measures of renal function appeared
to be greater in the GD8–12 group although serum BUN variability was also signiﬁcantly elevated in the GD13–17 group.
The increasing global range of C. raciborskii, the identiﬁcation
of other cyanobacterial species that have been shown to be
capable of producing CYN and the known adverse health
impacts of exposure to CYN in humans and other mammalian
species may be a cause for concern. Burns (2008) noted levels of
CYN ranging from 8.1 to 97.1 mg l-1 in treated drinking water from
Florida, an indication that that CYN may constitute a potential
health risk in the USA. Therefore, there is a need for an increased
research in numerous areas. The ﬁrst, and arguably the most
important, of these is a concerted eﬀort to produce large quantities of well-characterized CYN or CYN-containing algal lyophilates so that the needed research can be undertaken in multiple
laboratories. As long as CYN remains diﬃcult to obtain, research
eﬀorts will be impeded. Research priorities should include:
epidemiology studies to determine if there is an association
between CYN in drinking water and adverse health eﬀects similar
to those noted in the ‘Barcoo’ disease of the Australia outback for
which an association with CYN ingestion has been suggested
(Cleland, 1911; Hayman, 1992); the identiﬁcation of additional
potential toxicants in C. raciborskii and active metabolites of CYN;
the long-term eﬀects of CYN exposure including potential carcinogenicity, immunotoxicity, adverse eﬀects of prenatal exposure,
CNS toxicity, reproductive impairment and organ toxicity; the
course of CYN toxicity in the individual and the identiﬁcation of
the basal causes of the toxicity; the environmental eﬀects of the
spread of C. raciborskii; and the environmental conditions that
determine the amounts of CYN produced in blooms and the
retention of the CYN in bodies of water.
The study reported here was designed to make a thorough
assessment of the impact of CYN administered to adult mice by
i.p. injection during either early (GD8–12) or late (GD13–17) gestation and the subsequent recovery from the induced toxicity. A
range of endpoints including clinical observations, gross and
microscopic pathology, serum biochemistry and hepatic gene
expression were evaluated. The exposed animals exhibited toxic
eﬀects similar to those described in a human population (Palm
Island, Australia) exposed to CYN via chlorinated drinking water,
that is, gastrointestinal bleeding and hepatic and renal toxicity.
The similarity in response demonstrates that i.p. administration
of CYN in mice is a valid model for CYN-induced toxicity in
humans. The data indicate a signiﬁcant variability in individual
responses to CYN intoxication. Evidence of a return to normalcy
was noted by PD7 with a small number of exceptions. One week
after dosing, gastrointestinal bleeding was observed in a single
GD13–17 CYN-exposed animal and elevated liver/body weight
ratios were seen in the same dose group. Recovery appeared to
be complete at time points examined after 2 weeks post-dosing.

wileyonlinelibrary.com/journal/jat

A comparable rate of recovery was also noted for most genes
evaluated by RT-PCR although changes in the expression of speciﬁc genes (e.g. Gclc and hemopexin) persisted for up to 2 weeks
post-dosing. All gene expression levels had returned to normal
values by 4 weeks post-dosing.
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